Pain Management Medical Devices Gain Popularity

News provided by

Dec 07, 2016, 08:55 ET

NEW YORK, December 7, 2016 /PRNewswire/ --

Pain management has always been an important segment of the healthcare industry, yet medical devices designed to relieve pain have struggled to break into mainstream. This is primarily due to low awareness regarding the availability and use of such devices. Yet research reports suggest that this industry maybe gaining ground. According to a recent research by Markets and Markets the global pain management devices market is expected to grow at CAGR of 8.5% from 2016 to 2021, and reach a value of USD 4.64 Billion. Among the factors that contribute to the growth are the increasing demand for long-term pain management among the geriatric population, large patient population base, and new innovative technologies. Medovex Corp. (NASDAQ: MDVX), Abbott Laboratories (NYSE: ABT), St. Jude Medical Inc. (NYSE: STJ), Medtronic (NYSE: MDT), Zimmer Biomet Holdings Inc. (NYSE: ZBH)

Pain management devices are applied into various segments including neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, and more. According to the research, as of 2016, North America held the largest share of this market followed by Europe. However, the Asia-Pacific markets are expected to grow at the highest CAGR from 2016 to 2021. This is due to the continuously improving healthcare infrastructure in emerging markets of those regions.

Medovex Corp. (NASDAQ: MDVX) is biomedical device company with the mission of acquiring and developing a portfolio of potentially ground breaking medical technology products. According to the company, they focus on products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is designed to provide long lasting relief from pain associated with facet joint syndrome (osteoarthritis) at a much lower cost than currently available treatments.

Earlier this month, a Form 4 was filed disclosing publicly that Steve Gorlin, a Director of Medovex Corp. purchased shares at a $1.75, a premium to yesterday's closing price. Previously before that in November, Medovex Corp. named Jill Schweiger as its new Senior Vice President of Regulatory, Clinical and Quality. She has previously served as a Vice President and Director in at least six early stage medical device companies, as well as multinational med tech organizations such as Baxter Healthcare Corporation and Eli Lilly & Company.

Most recently, Schweiger served as Vice President, Clinical Studies & Regulatory Affairs for Flowonix Medical, Inc., a company focused on the development of implantable infusion pumps designed to deliver therapeutic drugs to relieve a variety of chronic disorders, such as spasticity and chronic intractable pain. While there, she was responsible for the development and execution of US and European regulatory and clinical strategies, that achieved PMA Approval in the US and CE Mark in Europe.

Patrick Kullmann, Medovex President and COO, stated, "We're pleased to have Jill join Medovex at such an exciting time in its evolution. As we seek CE Marking for the DenerveX System in the first half of 2017, her vast clinical studies and regulatory affairs background makes her ideally suited to fit this new role within our organization."

St. Jude Medical Inc. (NYSE: STJ) Spinal cord stimulation, a neurostimulation therapy proven to be effective for many chronic pain sufferers, helps mask pain by blocking or changing pain signals before they reach the brain. The company offers a stimulation in a new form of neurostimulation therapy, called BurstDR™. Doctors created this new therapy by understanding how the brain manages pain. The way it works is by mimicking natural patterns found in the brain and is believed to address both physical pain and the way it affects the patient emotionally.

Abbott Laboratories (NYSE: ABT) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Recently, the company's innovative handheld blood testing platform, i-STAT Alinity, received a CE mark, meaning the product is allowed to be commercialized in Europe and other countries. The company's core therapeutic areas include Gastroenterology, Women's Health, Cardiovascular, Pain/Central Nervous System, Respiratory and Influenza Vaccine.

Medtronic (NYSE: MDT) offers medical devices, such as Medtronic neurostimulators or drug pumps, which are surgically placed devices that modify pain signals before they reach the brain. Neurostimulators disrupt the pain signals traveling between the spinal cord and the brain so patients may feel relief and drug pumps deliver pain medication directly into the fluid surrounding the spinal cord. These treatments are reversible and a doctor is able to turn off or surgically remove the system.

Zimmer Biomet Holdings Inc. (NYSE: ZBH) is involved in designing, manufacturing and marketing orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The company's spine sector is a global leader in spine innovation, dedicated to enhancing the quality of life for spine patients worldwide by delivering comprehensive thoracolumbar, cervical, biologics, and implantable solutions, along with training and clinical support that support surgeons. The company offers solutions in MIS, Anterior Cervical, Posterior Cervical, Anterior/Lateral Thoracolumbar, Posterior Thoracolumbar, Biologics, and Implantable Stimulation.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and pr marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com expects to be compensated twelve thousand dollars for financial news dissemination and pr services by a non-affiliated third party for medovex corp. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:

Media Contact: [email protected] , +1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com